Publications

Detailed Information

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

DC Field Value Language
dc.contributor.authorKim, Miso-
dc.contributor.authorLee, Jeong-Ok-
dc.contributor.authorKoh, Jiwon-
dc.contributor.authorKim, Tae Min-
dc.contributor.authorLee, Ji Yun-
dc.contributor.authorJeon, Yoon Kyung-
dc.contributor.authorKeam, Bhumsuk-
dc.contributor.authorKim, Dong Wan-
dc.contributor.authorLee, Jong Seok-
dc.contributor.authorHeo, Dae Seog-
dc.date.accessioned2023-03-20T08:52:08Z-
dc.date.available2023-03-20T08:52:08Z-
dc.date.created2021-12-27-
dc.date.issued2021-08-
dc.identifier.citationHaematologica, Vol.106 No.8, pp.2277-2280-
dc.identifier.issn0390-6078-
dc.identifier.urihttps://hdl.handle.net/10371/189573-
dc.language영어-
dc.publisherFerrata Storti Foundation-
dc.titleA phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas-
dc.typeArticle-
dc.citation.journaltitleHaematologica-
dc.identifier.wosid000684588300007-
dc.identifier.scopusid2-s2.0-85111770179-
dc.citation.endpage2280-
dc.citation.number8-
dc.citation.startpage2277-
dc.citation.volume106-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorJeon, Yoon Kyung-
dc.contributor.affiliatedAuthorKim, Dong Wan-
dc.contributor.affiliatedAuthorLee, Jong Seok-
dc.type.docTypeLetter-
dc.description.journalClass1-
dc.subject.keywordPlusT-CELL LYMPHOMA-
dc.subject.keywordPlusOBJECTIVE RESPONSES-
dc.subject.keywordPlusMYCOSIS-FUNGOIDES-
dc.subject.keywordPlusSEZARY-SYNDROME-
dc.subject.keywordPlusCD30-
dc.subject.keywordPlusCRITERIA-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share